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 Measuring cardiac troponins is integral to diagnosing acute myocardial 
infarction (AMI); however, troponins may be elevated without AMI, 
and the use of multiple different assays confounds comparisons. We 
considered characteristics and serial troponin values in emergency 
department chest pain patients with and without AMI to interpret 
troponin excursions. We compared serial troponin in 124 AMI and 
non-AMI patients from the observational Performance of Triage Cardiac 
Markers in the Clinical Setting (PEARL) study who presented with chest 
pain and had at least one troponin value exceeding the 99th percentile 
of normal. Because 8 assays were used during data collection, we 
employed a method of scaling the troponin value to the correspond-
ing assay’s 99th percentile upper reference limit to standardize the 
results. In 81 AMI patients, 96% had elevated troponin at the first test 
following initial elevation, compared to 73% of the 43 non-AMI patients 
( P < 0.001). Scaling troponin to the 99th percentile of normal yielded 
a median value that was 4.8 [2.2, 14.1] times higher than the 99th 
percentile cutpoint among AMI patients, compared to 2.3 [1.5, 6.5] 
times higher among non-AMI patients ( P = 0.04). The rise in serial 
scaled troponin values distinguished the AMI patients. Scaling to the 
99th percentile was useful for comparing troponin when different 
assays were utilized. 
 H
igh-sensitivity troponin I testing has been shown to 
 improve the early diagnosis of acute myocardial in-
farction (AMI) and aid with risk stratiﬁ cation ( 1 – 3 ). 
Investigators using a registry in Australia and New 
Zealand determined that high-sensitivity troponin I testing 
was associated with fewer in-hospital adverse events for pa-
tients hospitalized with possible acute coronary syndrome 
( 4 ). Th ere are multiple non-AMI clinical scenarios, however, 
where troponin may exceed the 99th percentile, including 
renal failure, stroke, heart failure, pulmonary embolism, sepsis, 
and hypertension ( 5 ). We capitalized on a data set of chest 
pain patients who had serial troponin assays performed, had 
at least one positive value, and had central adjudication of 
the outcome of AMI. We compared the characteristics, as 
well as the dynamic rise and fall of troponin, in this group 
of patients to better understand how to quantitatively evalu-
ate the excursion of troponin and relate it to the conﬁ rmed 
diagnosis of AMI. 
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 METHODS 
 We performed retrospective analyses on data collected from 
a prospective, multicenter, observational study (Performance 
of Triage Cardiac Markers in the Clinical Setting [PEARL]) 
that examined the use of troponin for the diagnosis of AMI 
in patients ≥21 years of age who presented to the emergency 
department with symptoms of possible AMI from August 2014 
through February 2015. Patients with symptoms including 
sharp or dull chest pain, tightness, sensations of heavy weight 
on the chest, pain in the jaw or neck, pain radiating down the 
arms, and dyspnea were monitored for approximately 24 hours. 
A team of 3 experienced adjudicators (1 emergency physician 
and 2 cardiologists) independently reviewed case report forms 
and the 12-lead electrocardiogram recorded during initial evalu-
ation plus at least one additional electrocardiogram if obtained 
in the subject evaluation period to form a diagnosis of AMI 
or non-AMI using contemporary guideline deﬁ nitions ( 6 ). 
Discrepancies were discussed until consensus was reached. All 
institutions received institutional review board approval and 
patients’ informed consent prior to conducting this study. 
 Troponin was evaluated using one of the following tests: 
 Abbott ARCHITECT STAT TnI ( 7 ), Abbott i-STAT® POC 
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cTnI ( 8 ), Alere Triage® POC cTnI ( 9 ), Beckman Coulter 
 Access®  AccuTnI®+3 ( 10 ), Ortho VITROS® TnI ES ( 11 ), 
Roche  Cobas® TnT ( 12 ), Siemens ADVIA Centaur® TnI-Ultra 
( 13 ), or Siemens Dimension Vista® TnI ( 14 ). Th ese tests yielded 
results in diﬀ erent measurable ranges with unique 99th percen-
tile cutpoints. For that reason, we treated the data in two ways. 
First, we dichotomized the results as being either elevated or not 
elevated based on the 99th percentile cutoﬀ  rules for each assay. 
Second, to standardize the many troponin assays, we scaled the 
results using the ratio of the observed troponin value divided 
by the 99th percentile upper reference limit (“normal” value) 
( 15 ). For example, a patient with a troponin value of 0.1 ng/mL 
using the Roche Cobas® TnT, which has a 99th percentile up-
per reference limit of 0.01 ng/mL, would have a scaled result 
of 0.1/0.01 = 10. We interpret this as a troponin value that is 
10 times that of the 99th percentile of normal. We considered 
results from both methods across the sequence of troponin tests 
following the initial elevated result. 
 Continuous variables are reported as medians [quartile 1, 
quartile 3], and categorical variables are reported as frequencies 
(percent). Diﬀ erences between diagnosis groups were tested 
using Fisher’s exact test, 2-sample  t test, or Wilcoxon rank sum 
test, as appropriate. All analyses were conducted using SAS 
9.4, Cary, NC. 
 RESULTS 
 A total of 458 patients enrolled in the PEARL study from 
8 facilities. Of the 458 patients, 20 withdrew during the obser-
vation period, leaving a total of 438 patients who received an 
adjudicated diagnosis. Th ere were 1179 total troponin values, 
391 (33%) of which were greater than the corresponding 99th 
percentile upper reference limit. A total of 124 (28%) of the 
438 patients had at least one elevated troponin level and are 
the focus of this article. Eighty-one (65%) of the 124 patients 
were adjudicated as AMI and the remaining 43 (35%) as non-
AMI. Among these 124 patients, the AMI group was more 
likely to have previously known coronary artery disease than 
the non-AMI group (57% and 31%, respectively;  P = 0.008). 
Conversely, the AMI group was less likely to have renal failure 
compared to the non-AMI group (5% and 35%, respectively; 
 P < 0.001). Sample characteristics for the 124 patients with 
elevated troponin appear in  Table 1. 
 Th e median time from arrival to ﬁ rst elevated troponin was 
1.17 [0.70, 3.25] hours for AMI patients and 0.97 [0.60, 4.13] 
hours for non-AMI patients ( P = 0.08)  ( Figure 1 ). Addition-
ally, the median time between the ﬁ rst elevated troponin and 
subsequent test was 3.79 [2.25, 6.77] hours for AMI patients 
and 3.80 [2.25, 5.70] hours for non-AMI patients ( P = 0.81). 
Similarly, the median times between the ﬁ rst and second test 
following the initial elevation, as well as the second and third 
test following the initial elevation, did not diﬀ er ( P = 0.95 
and 0.37, respectively). Th e median number of troponin tests 
performed per patient until the ﬁ rst elevation occurred was 1 
for both AMI and non-AMI patients; however, the median 
total number of tests performed for AMI patients was 4 [3, 5], 
compared to 3 [2, 4] for non-AMI patients ( P = 0.01). 
 Table 1.  Study sample characteristics 
Acute myocardial infarction 
Variable Yes (n = 81) No (n = 43)  P value 
Age (years) 58.6 ± 11.1 57 ± 16.7 0.58 
Men 56 (69%) 28 (65%) 0.69 
Race 0.05 
Black 18 (22%) 17 (40%) 
Asian  0  1 (2%) 
White 56 (69%) 21 (51%) 
Other  7 (9%)  4 (9%) 
Atrial fibrillation 10 (12%)  6 (14%) 0.78 
Alcohol 15 (19%)  5 (12%) 0.44 
Arthritis  7 (9%)  4 (9%) 1.00 
Asthma  6 (7%)  8 (19%) 0.08 
Coronary artery disease 46 (57%) 13 (31%) 0.008 
Cancer 13 (16%)  6 (14%) 1.00 
Constipation  1 (1%)  1 (2%) 1.00 
Chronic obstructive pulmonary disease 10 (12%)  4 (10%) 0.77 
Diabetes 21 (26%) 18 (42%) 0.10 
Emphysema  2 (3%)  1 (2%) 1.00 
Gallstone  2 (3%)  0 0.54 
Hepatitis  2 (3%)  3 (7%) 0.34 
Liver cirrhosis  1 (1%)  0 1.00 
Systemic lupus erythematosus  1 (1%)  1 (2%) 1.00 
Migraine  0  2 (5%) 0.12 
Peripheral artery disease  4 (5%)  3 (7%) 0.69 
Renal failure  4 (5%) 15 (35%) <0.001 
Seizure  1 (1%)  3 (7%) 0.12 
Smoke 43 (53%) 17 (41%) 0.25 
Stroke  1 (1%)  3 (7%) 0.12 
Transient ischemic attack  2 (3%)  3 (7%) 0.34 
 Figure 1.  Hours from arrival at the emergency department to the first elevated 
troponin result by myocardial infarction diagnosis. 
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 Of the 124 patients who had at least one elevated troponin, 
114 (91.9%) had at least one subsequent test performed. Among 
the 77 retested AMI patients, 74 (96.1%) were conﬁ rmed to 
have elevated troponin on the following lab draw. In contrast, 
only 27 (73.0%) of the 37 retested non-AMI patients had an 
elevated result at the following test ( P < 0.001)  ( Figure 2 ). After 
the ﬁ rst elevated troponin, a diﬀ erence in the rate of eleva-
tion was not observed between AMI and non-AMI patients on 
the second or third subsequent lab draws ( P = 0.60 and 0.31, 
 respectively). 
 When considered as a continuous variable scaled to the 
99th percentile upper reference limit, we observed a median 
troponin that was 4.8 [2.2, 14.1] times higher than the upper 
limit of normal among AMI patients, compared to a median 2.3 
[1.5, 6.5] times higher than the upper limit of normal among 
non-AMI patients ( P = 0.04). Th e AMI group’s median tro-
ponin during the ﬁ rst test following the initial elevation was 
10.2 [3.4, 73.3] times that of normal compared to 2.0 [0.9, 
5.5] times that of normal for the non-AMI group ( P < 0.001). 
Further, the median paired diﬀ erence between patients’ ini-
tial elevated troponin and subsequent test was 4.1 [0.1, 39.7] 
for AMI patients and –0.2 [–1.6, 0.5] for non-AMI patients 
( P < 0.001). Additionally, the median scaled troponin was 16.7 
[4.3, 95.3] for AMI patients on the second lab draw following 
the initial elevated result, compared to 3.3 [2.0, 16.7] for non-
AMI patients ( P = 0.002). Finally, the median scaled troponin 
was 18.8 [4.0, 49.6] for AMI patients on the third lab draw 
following the initial elevation compared to 4.6 [2.1, 18.6] for 
non-AMI patients ( P = 0.03). To verify that these ﬁ ndings were 
not driven by an uneven utilization of assays between AMI and 
non-AMI patients, we conducted chi-square tests and conﬁ rmed 
that there were no signiﬁ cant diﬀ erences between the groups’ 
assays at any of the four lab draws analyzed ( P values = 0.30, 
0.31, 0.44, 0.07). Th e diﬀ erences and rates of change in median 
scaled troponin for AMI and non-AMI patients are shown in 
 Figure 3 and  Figure 4 , respectively. 
 DISCUSSION 
 Among 124 emergency department patients who presented 
with chest discomfort and at least one positive troponin value 
using contemporary sensitivity assays, 65.3% were conﬁ rmed 
to have AMI by an independent adjudication panel. Ninety-six 
percent of the AMI patients had conﬁ rmatory elevated tropo-
nins upon serial testing in the emergency department. Use of the 
99th percentile cutpoint of normal and scaling of the elevation 
to that anchor provided clear diﬀ erences in the excursions of 
troponin between those with and without AMI. 
 Our analyses provide a response to the criticisms regard-
ing the high rate of false-positive cases generated as a result of 
considering the 99th percentile cutoﬀ  as positive or negative 
on single tests ( 16 ,  17 ). Considering the change in serial values 
of troponin concentration scaled to the 99th percentile has 
previously been shown as superior to the 99th percentile cutoﬀ  
alone ( 18 ). After performing these analyses, we also considered 
the diﬀ erences in raw troponin values between AMI and non-
AMI patients at the 4 timepoints and found that they were in 
agreement with the scaled results ( P = 0.006, <0.001, <0.0001, 
0.04). Although using the raw and scaled values yielded similar 
statistical results, the conclusions drawn with the raw values 
were far more confounded due to the use of several assays, 
 Figure 2.  Rates of troponin elevation by diagnosis group and lab draw sequence. 
 Figure 3.  Median scaled troponin by diagnosis group and lab draw sequence. 
 Figure 4.  Rates of change in median scaled troponin by diagnosis. 
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whereas the scaled values oﬀ ered a standardized interpretation, 
regardless of assay. 
 We found that the ﬁ rst troponin test alone was not suf-
ﬁ ciently informative, nor was it elevated at an earlier time in 
those diagnosed as AMI or non-AMI. Th ere was a quantitative 
diﬀ erence in the rate of troponin elevation at the ﬁ rst test fol-
lowing initial elevation; however, a signiﬁ cant diﬀ erence in the 
rates of troponin elevation was not observed in the second and 
third subsequent draws following the initial elevation among 
AMI and non-AMI patients. Th is was likely attributed to the 
diﬀ ering rates of clinically driven retesting within each group 
over time. For example, only 23 (53.5%) patients without an 
AMI were tested ≥2 times after the initial elevation, compared 
to 67 (82.7%) of those retested with an AMI. Th is was not sur-
prising because AMI patients were more likely to have a history 
of coronary artery disease pointing to a higher clinical suspicion 
and a more assiduous approach to the diagnosis of AMI. 
 Although we did not observe signiﬁ cant diﬀ erences in di-
chotomized rates of troponin elevation at every lab draw, we did 
observe higher median scaled troponin values in AMI patients 
compared to non-AMI patients. As shown in  Figure 3 , the gradi-
ent of the troponin line sharply increased for those with AMI, 
while the line for those without AMI was relatively ﬂ at. Th is 
indicated that those with AMI had true ischemic rises, while 
those without AMI had slight elevations in troponin attributed 
to other causes. Th ese results conﬁ rmed the ﬁ ndings of a previ-
ous study, which suggested that the method of scaling troponin 
in terms of the 99th percentile is viable ( 19 ). In another study, 
patients with asymptomatic AMI (as diagnosed via electrocar-
diogram) were shown to have higher median high-sensitivity 
troponin I values than patients who did not have an AMI ( 20 ). 
Our results and those of others suggest that the interpretation 
of the excursion of serial troponin rather than single troponin 
values is critical in the diagnosis of AMI. 
 Th is work was a retrospective secondary analysis of an ob-
servational data cohort and is therefore subject to the inherent 
limitations of such studies. Th e study enrolled via convenience 
sample, so there is the potential for selection bias. We conducted 
analyses based on many diﬀ erent contemporary troponin as-
says, including troponin I and troponin T across a variety of 
laboratory platforms. Th e multiplicity of testing was clinically 
determined and was clearly biased by the physician’s suspicion of 
AMI. Troponin testing provides no information to distinguish 
between type 1 or type 2 myocardial infarction. Because this 
analysis considered only those patients with elevated troponin, 
our sample size was small, which limited the power and general-
izability of the results. Finally, we recognize that our study results 
may not generalize to populations with greater comorbidities, 
including renal failure, sepsis, heart failure, and other illnesses, 
where there may be greater proportions of troponin elevation 
or greater diﬃ  culty in determining AMI ( 21 – 23 ). 
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